So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
So-Young International Inc.NASDAQ: SY
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -CN¥50.65M, compared with -CN¥34.76M a year earlier. Trailing-twelve-month EBITDA was -CN¥203.21M.
Context
- EBITDA amounted to 12.3% of revenue in FY2025, up 9.7 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -CN¥140.05M (+23.1%) for the fiscal year ending Dec 2026, a step up from the -374.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CN¥50.65M+9.5% QoQ
- Last fiscal yearDec 2025
- -CN¥182.19M-374.5% YoY
- LTMMar 2026
- -CN¥203.21M-983.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.7% | +25.2% | +70.9 pp |
| 1 year | -374.5% | +23.1% | +397.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CNY · from the income statement
- Latest · FY2025
- (182.19M) CNY
- Year-over-year change
- -374.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (182.19M) | -374.5% |
| FY2024 | 2024-12-31 | (38.39M) | -171.2% |
| FY2023 | 2023-12-31 | 53.96M | +234.9% |
| FY2022 | 2022-12-31 | (39.99M) | -163.1% |
| FY2021 | 2021-12-31 | 63.39M | — |
EBITDA vs competitors
How SY compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -983.4% is the lowest of 11, against a peer median of +5.2%.
- EBITDA amounts to 12.3% of revenue for SY, versus a peer median of 53.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $92.9M USD | +159.9% | — | 939.0% | |
| LTM Feb 2026 | $17.31M USD | +4.6% | -7.7% | 21.5% | |
| LTM Mar 2026 | $5M USD | -88.2% | +10.6% | 1.2% | |
| LTM Apr 2026 | -$6.2M USD | -108.2% | -68.7% | 0.7% | |
| LTM Mar 2026 | -$17.44M USD | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$66.08M USD | -31.0% | — | 81.4% | |
| LTM Mar 2026 | -$81.51M USD | +5.7% | — | 94.5% | |
| LTM Mar 2026 | -$83.2M USD | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -CN¥203.21M CNY | -983.4% | — | 12.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M USD | +15.4% | — | — |
| LTM Mar 2026 | -$220.73M USD | -23.8% | — | — | |
| Peer median (excluding SY) | — | +5.2% | -7.7% | 53.2% | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.26B | 1.5B | 1.47B | 1.48B |
| Cost of Revenue | 327.89M | 393.29M | 544.34M | 567.59M | 774.04M |
| Gross Profit | 1.36B | 864.58M | 953.69M | 899.11M | 707.86M |
| Gross Margin | 80.6% | 68.7% | 63.7% | 61.3% | 47.8% |
| Research & Development | 286.57M | 235.09M | 203.52M | 165.03M | 133.31M |
| Selling, General & Admin | 1.04B | 732.3M | 811.22M | 818.57M | 833.76M |
| Operating Expenses | 1.4B | 967.39M | 1.01B | 1.52B | 967.07M |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 46.09M | 57.21M |
| EBITDA | 63.39M | (39.99M) | 53.96M | (38.39M) | (182.19M) |
| EBITDA Margin | 3.7% | -3.2% | 3.6% | -2.6% | -12.3% |
| Operating Income | (32.57M) | (102.81M) | (61.05M) | (624.49M) | (259.21M) |
| Operating Margin | -1.9% | -8.2% | -4.1% | -42.6% | -17.5% |
| Interest Income | 19.33M | 28.88M | 48.84M | 46.51M | 24.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16.17M | 15.73M | 68.92M | 36.41M | 19.8M |
| Income Before Tax | (16.41M) | (87.07M) | 7.87M | (588.09M) | (239.4M) |
| Pre-Tax Margin | -1.0% | -6.9% | 0.5% | -40.1% | -16.2% |
| Income Tax Expense | 21.23M | (20.97M) | (18.08M) | (905K) | (774.31K) |
| Net Income | (8.37M) | (65.55M) | 21.28M | (589.53M) | (235.7M) |
| Net Margin | -0.5% | -5.2% | 1.4% | -40.2% | -15.9% |
| EPS (Basic) | (0.06) | (0.48) | 0.16 | (4.40) | (1.78) |
| EPS (Diluted) | (0.06) | (0.48) | 0.16 | (4.39) | (1.78) |
| Weighted Avg Shares | 138.04M | 138.04M | 133.19M | 134.09M | 131.59M |
| Weighted Avg Shares (Diluted) | 138.04M | 138.04M | 131.91M | 134.16M | 131.59M |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.